Article

Next-generation calcineurin inhibitor in pivotal trials for noninfectious uveitis

Enrollment has been completed in a series of phase III studies investigating voclosporin (Lumeniq, Lux Biosciences) as a steroid-sparing agent for the treatment of noninfectious uveitis, according to Quan Dong Nguyen, MD, assistant professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore.

Enrollment has been completed in a series of phase III studiesinvestigating voclosporin (Lumeniq, Lux Biosciences) as asteroid-sparing agent for the treatment of noninfectious uveitis,according to Quan Dong Nguyen, MD, assistant professor ofophthalmology, Wilmer Eye Institute, Johns Hopkins UniversitySchool of Medicine, Baltimore.

Voclosporin, formerly known as LX211, is a next-generationcalcineurin inhibitor that, based on its evaluation in otherindications, appears to have a better safety profile comparedwith other calcineurin inhibitors, including cyclosporine A andtacrolimus. In addition, results from evaluation of voclosporinin experimental models of autoimmune uveitis showed its use wasassociated with preservation of retinal structure andfunction.

Three pivotal studies are being conducted as part of the LUMINATE(Lux Uveitis Multicenter Investigation of a New Approach toTrEatment) clinical trial program. One is investigating thetreatment of active intermediate, anterior and intermediate,posterior or panuveitis; a second is evaluating voclosporin formaintaining control of inflammation in patients with quiescentintermediate, anterior and intermediate, posterior or panuveitis;and the third enrolled patients with active anterior segmentuveitis.

The studies are being conducted in centers across the UnitedStates, Canada, India, and Europe and include about 550 patientstotal. Each study has a dose-ranging design with threevoclosporin treatment groups and a placebo control group. Allstudies include corticosteroid tapering to 0.5 mg/day ofprednisone, and the maintenance study protocol involveswithdrawal of concomitant immunomodulatory therapy.

"These trials are important because they represent the firstprospective, placebo-controlled, masked clinical trials designedto seek an indication for a steroid-sparing drug specificallyintended for uveitis," Dr. Nguyen said. "In addition, the datacollected should provide us information on the natural history ofuveitis and patient quality of life.

"The future of uveitis therapy seems bright, but for now, westill need to adhere to a therapeutic goal of accepting notolerance for any degree of inflammation," he concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.